GenSight Biologics integrates the Enternext PEA-PME 150 index
Paris, France, October 2, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announces its inclusion, as of today, in the Enternext® PEA-PME 150 index following its annual review.
Please find the full PDF press release attached.
Contacts
GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20 |
NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55 |
Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017 |
Source: GenSight Biologics